Disclaimer:
Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.
ERAXIS
Overview
What is ERAXIS?
ERAXIS for Injection is a sterile, lyophilized product for intravenous (IV) infusion that contains anidulafungin. ERAXIS (anidulafungin) is a semi-synthetic lipopeptide synthesized from a fermentation product of . Anidulafungin is an echinocandin, a class of antifungal drugs that inhibits the synthesis of 1,3-β-D-glucan, an essential component of fungal cell walls.
ERAXIS (anidulafungin) is 1-[(4R,5R)-4,5-dihydroxy-N-[[4"-(pentyloxy)[1,1':4',1"-terphenyl]-4-yl]carbonyl]-L-ornithine]echinocandin B. Anidulafungin is a white to off-white powder that is practically insoluble in water and slightly soluble in ethanol. In addition to the active ingredient, anidulafungin, ERAXIS for Injection contains the following inactive ingredients:
50 mg/vial
100 mg/vial
The empirical formula of anidulafungin is CHNO and the formula weight is 1140.3.
The structural formula is:
Prior to administration, ERAXIS for Injection requires reconstitution with sterile Water for Injection and subsequent dilution with either 5% Dextrose Injection, USP or 0.9% Sodium Chloride Injection, USP (normal saline).
DO NOT dilute with other solutions or co-infuse with other medications or electrolytes []
What does ERAXIS look like?
What are the available doses of ERAXIS?
Lyophilized powder for injection: 50 mg per vial
Lyophilized powder for injection: 100 mg per vial
What should I talk to my health care provider before I take ERAXIS?
How should I use ERAXIS?
ERAXIS is indicated for use in adults for the treatment of the following fungal infections listed below. Specimens for fungal culture and other relevant laboratory studies (including histopathology) should be obtained prior to therapy to isolate and identify causative organism(s). Therapy may be instituted before the results of the cultures and other laboratory studies known. However, once these results become available, antifungal therapy should be adjusted accordingly.
Candidemia and other forms of infections: 200 mg loading dose on Day 1, followed by 100 mg daily dose thereafter for at least 14 days after the last positive culture ()
Esophageal candidiasis: 100 mg loading dose on Day 1, followed by 50 mg daily dose thereafter for a minimum of 14 days and for at least 7 days following resolution of symptoms ()
The rate of infusion should not exceed 1.1 mg/minute [equivalent to 1.4 mL/minute or 84 mL/hour when reconstituted and diluted per instructions] (, )
What interacts with ERAXIS?
Sorry No Records found
What are the warnings of ERAXIS?
Sorry No Records found
What are the precautions of ERAXIS?
Sorry No Records found
What are the side effects of ERAXIS?
Sorry No records found
What should I look out for while using ERAXIS?
ERAXIS is contraindicated in persons with known hypersensitivity to anidulafungin, any component of ERAXIS, or other echinocandins.
What might happen if I take too much ERAXIS?
During clinical trials a single 400 mg dose of ERAXIS was inadvertently administered as a loading dose. No clinical adverse events were reported. In a study of 10 healthy subjects administered a loading dose of 260 mg followed by 130 mg daily, ERAXIS was generally well tolerated; 3 of the 10 subjects experienced transient, asymptomatic transaminase elevations (≤3 x ULN) [].
Anidulafungin is not dialyzable.
The maximum non-lethal dose of anidulafungin in rats was 50 mg/kg, a dose which is equivalent to 10 times the recommended daily dose for esophageal candidiasis (50 mg/day) or equivalent to 5 times the recommended daily dose for candidemia and other infections (100 mg/day), based on relative body surface area comparisons.
How should I store and handle ERAXIS?
Buspirone HCl Tablets USP are supplied as follows:5 mg tablets: White to off-white, oval, biconvex, scored tablets, debossed WATSON and 657, in bottles of 100, 500, and 1000.10 mg tablets: White to off-white, oval, biconvex, scored tablets, debossed WATSON and 658, in bottles of 100, 500, and 1000.15 mg tablets:White to off-white, oval shaped, scored tablets, debossed with the Watson logo and 718, and scoring on both sides so it can be either bisected or trisected, in bottles of 60, 180, 500, and 1000.Store at 20° - 25°C (68°- 77°F). [See USP Controlled Room Temperature]. Protect from temperatures greater than 30°C (86°F).Dispense in a tight, light-resistant container as defined in USP/NF.Buspirone HCl Tablets USP are supplied as follows:5 mg tablets: White to off-white, oval, biconvex, scored tablets, debossed WATSON and 657, in bottles of 100, 500, and 1000.10 mg tablets: White to off-white, oval, biconvex, scored tablets, debossed WATSON and 658, in bottles of 100, 500, and 1000.15 mg tablets:White to off-white, oval shaped, scored tablets, debossed with the Watson logo and 718, and scoring on both sides so it can be either bisected or trisected, in bottles of 60, 180, 500, and 1000.Store at 20° - 25°C (68°- 77°F). [See USP Controlled Room Temperature]. Protect from temperatures greater than 30°C (86°F).Dispense in a tight, light-resistant container as defined in USP/NF.Buspirone HCl Tablets USP are supplied as follows:5 mg tablets: White to off-white, oval, biconvex, scored tablets, debossed WATSON and 657, in bottles of 100, 500, and 1000.10 mg tablets: White to off-white, oval, biconvex, scored tablets, debossed WATSON and 658, in bottles of 100, 500, and 1000.15 mg tablets:White to off-white, oval shaped, scored tablets, debossed with the Watson logo and 718, and scoring on both sides so it can be either bisected or trisected, in bottles of 60, 180, 500, and 1000.Store at 20° - 25°C (68°- 77°F). [See USP Controlled Room Temperature]. Protect from temperatures greater than 30°C (86°F).Dispense in a tight, light-resistant container as defined in USP/NF.Buspirone HCl Tablets USP are supplied as follows:5 mg tablets: White to off-white, oval, biconvex, scored tablets, debossed WATSON and 657, in bottles of 100, 500, and 1000.10 mg tablets: White to off-white, oval, biconvex, scored tablets, debossed WATSON and 658, in bottles of 100, 500, and 1000.15 mg tablets:White to off-white, oval shaped, scored tablets, debossed with the Watson logo and 718, and scoring on both sides so it can be either bisected or trisected, in bottles of 60, 180, 500, and 1000.Store at 20° - 25°C (68°- 77°F). [See USP Controlled Room Temperature]. Protect from temperatures greater than 30°C (86°F).Dispense in a tight, light-resistant container as defined in USP/NF.Buspirone HCl Tablets USP are supplied as follows:5 mg tablets: White to off-white, oval, biconvex, scored tablets, debossed WATSON and 657, in bottles of 100, 500, and 1000.10 mg tablets: White to off-white, oval, biconvex, scored tablets, debossed WATSON and 658, in bottles of 100, 500, and 1000.15 mg tablets:White to off-white, oval shaped, scored tablets, debossed with the Watson logo and 718, and scoring on both sides so it can be either bisected or trisected, in bottles of 60, 180, 500, and 1000.Store at 20° - 25°C (68°- 77°F). [See USP Controlled Room Temperature]. Protect from temperatures greater than 30°C (86°F).Dispense in a tight, light-resistant container as defined in USP/NF.Buspirone HCl Tablets USP are supplied as follows:5 mg tablets: White to off-white, oval, biconvex, scored tablets, debossed WATSON and 657, in bottles of 100, 500, and 1000.10 mg tablets: White to off-white, oval, biconvex, scored tablets, debossed WATSON and 658, in bottles of 100, 500, and 1000.15 mg tablets:White to off-white, oval shaped, scored tablets, debossed with the Watson logo and 718, and scoring on both sides so it can be either bisected or trisected, in bottles of 60, 180, 500, and 1000.Store at 20° - 25°C (68°- 77°F). [See USP Controlled Room Temperature]. Protect from temperatures greater than 30°C (86°F).Dispense in a tight, light-resistant container as defined in USP/NF.
Clinical Information
Chemical Structure
No Image foundClinical Pharmacology
Anidulafungin is an anti-fungal drug []
Non-Clinical Toxicology
ERAXIS is contraindicated in persons with known hypersensitivity to anidulafungin, any component of ERAXIS, or other echinocandins.Psychotropic Agents
Amitriptyline
Diazepam
Haloperidol
Nefazodone
Trazodone
Triazolam/Flurazepam
Other Psychotropics
Laboratory abnormalities in liver function tests have been seen in healthy volunteers and patients treated with ERAXIS. In some patients with serious underlying medical conditions who were receiving multiple concomitant medications along with ERAXIS, clinically significant hepatic abnormalities have occurred. Isolated cases of significant hepatic dysfunction, hepatitis, or hepatic failure have been reported in patients; a causal relationship to ERAXIS has not been established. Patients who develop abnormal liver function tests during ERAXIS therapy should be monitored for evidence of worsening hepatic function and evaluated for risk/benefit of continuing ERAXIS therapy.
The most serious adverse reactions reported with ERAXIS are:
Reference
This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"
While we update our database periodically, we cannot guarantee it is always updated to the latest version.
Review
Read user comments about the side effects, benefits, and effectiveness of losartan oral.
Overall User Ratings
515Total User Reviews
User Reviews
Learn about
User Reviews
Professional
Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72Tips
Tips
Interactions
Interactions
A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).